The candidate is being developed with a Toll-like receptor 3 (TLR3) agonist adjuvant for multiple indications, including cervical intraepithelial neoplasia (also known as cervical dysplasia or CIN), genital warts, cervical cancer, and head and neck cancers.
#Non-specific immunostimulants act irrespective of antigenic specificity to augment immune response of other antigen or stimulate components of the immune system without antigenic specificity, such as adjuvants and non-specific immunostimulators.
In June 2008, Nventa announced the development of a proprietary vaccine adjuvant, Poly IC – Poly Arginine (Poly-ICR), for use with both therapeutic and prophylactic vaccines.
•
Nventa is developing HspE7 in combination with the Toll-like receptor 3 (TLR3) agonist adjuvant Poly-ICLC for multiple indications, including Cervical Intraepithelial Neoplasia (also known as cervical dysplasia or CIN), Genital Warts, Cervical Cancer, and head and neck cancers.
Immunologic adjuvants are substances, administered in conjunction with a vaccine, that stimulate the immune system and increase the response to the vaccine.